Targeted Medical Therapy of Biliary Tract Cancer: Recent Advances and Future Perspectives

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2008 Dec 17

PMID 19084910

Citations 4

Authors

Michael Hopfner

Detlef Schuppan

Hans Scherubl

Affiliations

Soon will be listed here.

Abstract

The limited efficacy of cytotoxic therapy for advanced biliary tract and gallbladder cancers emphasizes the need for novel and more effective medical treatment options. A better understanding of the specific biological features of these neoplasms led to the development of new targeted therapies, which take the abundant expression of several growth factors and cognate tyrosine kinase receptors into account. This review will briefly summarize the status and future perspectives of antiangiogenic and growth factor receptor-based pharmacological approaches for the treatment of biliary tract and gallbladder cancers. In view of multiple novel targeted approaches, the rationale for innovative therapies, such as combinations of growth factor (receptor)-targeting agents with cytotoxic drugs or with other novel anticancer drugs will be highlighted.

Citing Articles

Inhibitory effect of isomorellin on cholangiocarcinoma cells via suppression of NF-κB translocation, the phosphorylated p38 MAPK pathway and MMP-2 and uPA expression.

Hahnvajanawong C, Sahakulboonyarak T, Boonmars T, Reutrakul V, Kerdsin A, Boueroy P Exp Ther Med. 2021; 21(2):151.

PMID: 33456518 PMC: 7792505. DOI: 10.3892/etm.2020.9583.

Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer.

Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A Mol Cell Biochem. 2014; 396(1-2):257-68.

PMID: 25064451 DOI: 10.1007/s11010-014-2161-9.

Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells.

Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C Int J Biol Sci. 2012; 8(1):15-29.

PMID: 22211101 PMC: 3226029. DOI: 10.7150/ijbs.8.15.

Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.

Roth J, Carlson J J Gastrointest Cancer. 2011; 43(2):215-23.

PMID: 21234709 DOI: 10.1007/s12029-010-9242-0.

References

Burtrum D, Zhu Z, Lu D, Anderson D, Prewett M, Pereira D . A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003; 63(24):8912-21. View

Leary A, Johnston S . Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest. 2007; 25(5):347-65. DOI: 10.1080/07357900701259694. View

Ustundag Y, Bronk S, Gores G . Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol. 2007; 13(6):851-7. PMC: 4065919. DOI: 10.3748/wjg.v13.i6.851. View

Tai C, Chiou H, Wu C, Pan S, Liu J . Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin. Onkologie. 2006; 29(4):179-80. DOI: 10.1159/000091751. View

Maki R, Kraft A, Scheu K, Yamada J, Wadler S, Antonescu C . A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005; 103(7):1431-8. DOI: 10.1002/cncr.20968. View

Renshaw K . MALIGNANT NEOPLASMS OF THE EXTRAHEPATIC BILIARY DUCTS. Ann Surg. 1922; 76(2):205-21. PMC: 1400046. DOI: 10.1097/00000658-192208000-00008. View

Maione P, Gridelli C, Troiani T, Ciardiello F . Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006; 11(3):274-84. DOI: 10.1634/theoncologist.11-3-274. View

Wang Z, Ruan Y, Guan Y, Liu S . Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol. 2003; 9(2):267-70. PMC: 4611325. DOI: 10.3748/wjg.v9.i2.267. View

Carriaga M, Henson D . Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995; 75(1 Suppl):171-90. DOI: 10.1002/1097-0142(19950101)75:1+<171::aid-cncr2820751306>3.0.co;2-2. View

10.

Lu C, Wyszomierski S, Tseng L, Sun M, Lan K, Neal C . Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007; 13(19):5883-8. DOI: 10.1158/1078-0432.CCR-06-2837. View

11.

Salisbury A, Macaulay V . Development of molecular agents for IGF receptor targeting. Horm Metab Res. 2004; 35(11-12):843-9. DOI: 10.1055/s-2004-814158. View

12.

Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser S, Alpini G . Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006; 169(3):877-88. PMC: 1698823. DOI: 10.2353/ajpath.2006.050464. View

13.

Scotlandi K, Manara M, Nicoletti G, Lollini P, Lukas S, Benini S . Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005; 65(9):3868-76. DOI: 10.1158/0008-5472.CAN-04-3192. View

14.

Tao Y, Pinzi V, Bourhis J, Deutsch E . Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007; 4(10):591-602. DOI: 10.1038/ncponc0934. View

15.

Schwartz R, Davidson T . Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2005; 18(14 Suppl 11):14-21. View

16.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

17.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

18.

Hopfner M, Sutter A, Huether A, Baradari V, Scherubl H . Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol. 2006; 12(35):5635-43. PMC: 4088163. DOI: 10.3748/wjg.v12.i35.5635. View

19.

Patel T . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; 2:10. PMC: 113759. DOI: 10.1186/1471-2407-2-10. View

20.

Philip P, Mahoney M, Allmer C, Thomas J, Pitot H, Kim G . Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006; 24(19):3069-74. DOI: 10.1200/JCO.2005.05.3579. View